Lantheus Holdings, Inc. Derivative Asset
Lantheus Holdings, Inc. (LNTH) had Derivative Asset of $1.33 million as of 2020-03-31, per its 10-Q filed 2020-04-30.
Discontinued › Balance Sheet › Assets
us-gaap:DerivativeAssets · last filed 2020-04-30
- 2020-03-31: Derivative Asset $1.33M.
| Period end | Derivative Asset |
|---|---|
| 2020-03-31 | $1.33M 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |